Current role of gemcitabine in the treatment of Hodgkin lymphoma.
about
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary resultsGemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
P2860
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
@en
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
@nl
type
label
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
@en
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
@nl
prefLabel
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
@en
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
@nl
P2860
P1433
P1476
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
@en
P2093
Anas Younes
Yasuhiro Oki
P2860
P304
P356
10.1080/10428190801911704
P577
2008-05-01T00:00:00Z